Phase 1CompletedINTERVENTIONAL
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
ClinicalTrials.gov · NCT06648031 · Registry updated: 2026-01-12
- Condition / research focus
- Type2diabetes
- Sponsor
- Lexaria Bioscience Corp.
- Countries with listed sites
- Australia
- Registry dates and results
- Start: 2024-12-04. Completion: 2025-07-31 (may be estimated). No results posted in this registry response.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Arm 1 - DehydraTECH-CBD alone (drug)
- Arm 2 - DehydraTECH-semaglutide alone (drug)
- Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide (drug)
- Arm 4 - Rybelsus medication (semaglutide) alone (drug)
- Arm 5- Tirzepatide (drug)
Where the study takes place — 7 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Paratus Clinical Pty Ltd, Blacktown Trial Clinic
Blacktown, New South Wales, Australia
Site recruitment: Not reported - Emeritus - Sydney
Botany, New South Wales, Australia
Site recruitment: Not reported - Canopy Clinical Sutherland
Miranda, New South Wales, Australia
Site recruitment: Not reported - Canopy Clinical Wollongong
Wollongong, New South Wales, Australia
Site recruitment: Not reported - Paratus Clinical Brisbane Pty Ltd
Herston, Queensland, Australia
Site recruitment: Not reported - CMAX Clinical Research
Adelaide, South Australia, Australia
Site recruitment: Not reported - Emeritus - Melbourne
Camberwell, Victoria, Australia
Site recruitment: Not reported